SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (10728)3/1/2004 4:17:27 AM
From: Robohogs  Respond to of 52153
 
See my note on SEPR board but JPM is out over night pounding the table on SEPR with a price target of $57. They see very strong outcome here with delay of 3-6 months in launch but very strong label overcoming delay - drop 2004 revs to stocking number, and raise 2006 substantially (50%). Think drug could be 25% share of $4 mkt eventually - seems to assume PFE will win marketing battle. Says label is very much superior to Ambien.

Jon


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News